Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub‐Analysis From the PREFER in AF ( PRE vention o F Thromboembolic Events– E uropean R egistry in A trial F ibrillation)

Figure 1. Incidence of thromboembolic events (stroke/TIA/systemic embolism) at 1 year in patients aged <85 and ≥85 years. Rates of thromboembolic events according to 3 age strata (<75, 75–84, and ≥85 years) are also depicted. TIA indicates transient ischemic attack.

Figure 2. Incidence of major bleeding at 1 year in patients aged <85 and ≥85 years. Rates of major bleeding according to 3 age strata (<75, 75–84, and ≥85 years) are also depicted.

Figure 3. A, Incidence of thromboembolic events (stroke/TIA/SEE) in patients aged <85 and ≥85 years receiving OAC or no OAC (antiplatelet therapy only or no antithrombotic drug). B, Risk of thromboembolic events by 5‐year intervals of age increase in patients receiving OAC vs no OAC. antiPLT indicates antiplatelet; OAC, oral anticoagulant therapy; SEE, systemic embolic event; TIA, transient ischemic attack; TRT, .

Figure 4. A, Incidence of major bleeding in patients aged <85 and ≥85 years receiving OAC or no OAC (antiplatelet therapy only or no antithrombotic drug). B, Risk of thromboembolic events by 5‐year intervals of age increase in patients receiving OAC vs no OAC. antiPLT indicates antiplatelet therapy; OAC, oral anticoagulant therapy; TRT, .

Figure 5. Net clinical benefit, adjusted for the mortality risk, of OAC vs no OAC (antiplatelet therapy only or no antithrombotic drug) according to different age strata, including ischemic stroke, systemic embolism, myocardial infarction, hemorrhagic stroke, and major bleeding as outcome measures. OAC indicates oral anticoagulant therapy.